90 completed, 15 terminated, 14 unknown, 4 withdrawn. 33 Phase 3, 31 Phase 1, 23 Phase 2, 21 Phase 4, 11 Not applicable.
Follow Voriconazole: new trials by email Literature Review of Voriconazole trials Research Report on Voriconazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Drug Interaction Between Buagafuran and Voriconazole Buagafuran, Voriconazole - Drug Drug Interaction (DDI) | Phase 1 | Not yet recruiting | Beijing Union Pharmaceutical Factory Ltd | 18 | 2026-04-01 | 2026-03-09 |
| Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects Dexamethasone, CYP Probe Cocktail, voriconazole - Drug-Drug Interactions | Phase 1 | Not yet recruiting | Min Kyu Park | 12 | 2026-04-01 | 2026-02-23 |
| Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy EL219, Active Comparator- IV Antifungal (LAmB or voriconazole) - Invasive Mould Infection | Phase 2 | Recruiting | Elion Therapeutics, Inc. | 60 | 2026-02-13 | 2026-10-05 |
| Rezafungin Prophylaxis in Liver Transplant Rezafungin, Standard of care antifungal prophylaxis - Liver Transplant Infection, Fungal Infection | Phase 3 | Enrolling by invitation | Fernanda P Silveira, MD, MS | 385 | 2025-10-15 | 2026-09-29 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years ABS-1230, Placebo, Omeprazole - KCNT1-Related Epilepsy | Phase 1 | Recruiting | Actio Biosciences, Inc. | 92 | 2025-08-28 | 2026-08-07 |
| Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections Voriconazole high dose, Voriconazole low dose - Dermatophyte Infection | Phase 2 | Not yet recruiting | Sheikh Zayed Medical College | 120 | 2024-11-15 | 2024-11-08 |
| A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants Repotrectinib, Voriconazole, Quinidine - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 32 | 2024-08-26 | 2025-08-22 |
| Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics Combined with voriconazole, Combined with caspofungin, Tacrolimus-alone treatment - Kidney Transplant Patients | Completed | LI YAN | 507 | 2022-09-01 | 2023-09-28 | |
| Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels Vesatolimod, Cobicistat, Voriconazole - Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 1 | Terminated | Gilead Sciences | 18 | 2022-08-19 | 2024-12-03 |
| Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy Venetoclax, Azacitidine, Decitabine - Acute Myeloid Leukemia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 24 | 2022-06-01 | 2026-08-21 |
| Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status Voriconazole 200mg, FluvoxaMINE 50 Mg Oral Tablet, Omeprazole 10 MG Oral Tablet - Healthy | Phase 1 | Unknown | University Hospital, Geneva | 45 | 2022-04-01 | 2022-11-03 |
| Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis Intralesional Sodium stibogluconate, Intralesional Cryotherapy, Intralesional Voriconazole - Leishmaniasis, Cutaneous | Phase 3 | Unknown | Zagazig University | 136 | 2022-01-01 | 2023-08-29 |
| The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution, Ceftazidime 5% + vancomycin 5%, Gentamicin 1.4% + vancomycin 5% - Bacterial Keratitis, Fungal Keratitis | Completed | Alexandria University | 123 | 2021-12-31 | 2024-01-25 | |
| Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies AZD0466, Voriconazole - Haematological Malignancies | Phase 1 | Terminated | AstraZeneca | 46 | 2021-06-11 | 2025-06-15 |
| Azole-echinocandin Combination Therapy for Invasive Aspergillosis Azole, Anidulafungin - Invasive Aspergillosis | Phase 3 | Terminated | Erasmus Medical Center | 66 | 2021-05-11 | 2024-05-07 |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Ibrutinib, ECG, PFT's - Chronic GVHD | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2021-05-10 | 2026-01-23 |
| Combination of Oral Antifungal Treatment for Refractory Dermatophytosis Group A (TF group) receiving Oral Terbinafine (250 mg once daily) and Fluconazole (100 mg twice daily); 48 patients - Dermatophytosis | Not applicable | Completed | Chittagong Medical College | 138 | 2021-03-01 | 2026-09-11 |
| A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis Itraconazole 200 mg, Voriconazole 200mg - Chronic Pulmonary Aspergillosis | Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 116 | 2021-03-01 | 2024-08-14 |
| Three Induction Treatments on Cryptococcal Meningitis Voriconazole 200mg, amphotericin B deoxycholate (0.4-0.5mg/kg/d), Amphotericin B-deoxycholate (0.7-1.0mg/kg/d) - Cryptococcal Meningitis, HIV/AIDS | Early Phase 1 | Unknown | First Affiliated Hospital of Zhejiang University | 120 | 2021-01-25 | 2021-02-02 |
| Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Zanubrutinib, Fluconazole, Diltiazem - B-cell Malignancies | Phase 1 | Completed | BeiGene | 26 | 2020-11-15 | 2024-10-26 |
Showing 20 of 131. Sign in to see all of them.
Mycoses (26) · Aspergillosis (22) · Invasive Fungal Infections (11) · Candidiasis (8) · Hematologic Neoplasms (8) · Infections (8) · Candidemia (7) · Invasive Pulmonary Aspergillosis (6) · Leukemia (6) · Leukemia, Myeloid, Acute (5) · Neutropenia (5) · Acquired Immunodeficiency Syndrome (4) · Candidiasis, Invasive (4) · Eye Infections, Fungal (3) · Fungemia (3)
Pfizer (30) · National Cancer Institute (NCI) (6) · Seoul National University Hospital (5) · Astellas Pharma Inc (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · University of California, San Francisco (3) · Astellas Pharma Global Development, Inc. (2) · Bristol-Myers Squibb (2) · Dokuz Eylul University (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Yung Shin Pharm. Ind. Co., Ltd. (2) · Abdul Wali Khan University Mardan (1) · Actio Biosciences, Inc. (1)
United States (53) · Canada (12) · China (12) · France (12) · Germany (12) · India (12) · South Korea (12) · Belgium (11) · Spain (10) · United Kingdom (9) · Italy (8) · Netherlands (8) · Australia (7) · Switzerland (7) · Russia (6)
Mukaddes Gumustekin, Professor, MD, PhD (2) · NV Prajna, DNB, FRC Ophth (2) · Nisha Acharya, MD, MS (2) · Thomas J. Walsh, MD (2) · Tom Lietman, MD (2) · Adam Reich, MD, PhD (1) · Alan Gamis (1) · Amira A Nayel, PharmD (1) · Angela Smith, M.D. (1) · Bart Rijnders, MD, PhD (1) · Caroline Samer, Prof (1)
PMID 28459966, PMID 28597967, PMID 31280481, PMID 33891293, PMID 27636722, PMID 32557558, PMID 15232472, PMID 20547942, PMID 20826719, PMID 21383338, PMID 22042283, PMID 22420668, PMID 22503212, PMID 22761409, PMID 23065438, PMID 23702779, PMID 23710653, PMID 23939898, PMID 23943184, PMID 24559321, PMID 24913161, PMID 24914120, PMID 25451051, PMID 25599346, PMID 25645660, PMID 25764482, PMID 25841317, PMID 25902926, PMID 26531051, PMID 26684607, PMID 26904404, PMID 27054515, PMID 27600044, PMID 27787540, PMID 28426856, PMID 28472247, PMID 28614691, PMID 28645776, PMID 28817744, PMID 30049743, PMID 30289478, PMID 32304015, PMID 32457995, PMID 32468741, PMID 33136159, PMID 33549194, PMID 33680981, PMID 34970774, PMID 35024776, PMID 35191210
2008 (2), 2009 (2), U10EY018573 (2), 2005 (1), 2015 (1), 2017 (1), 2018 (1), 2019 (1), R01GM078501 (1), U01HL069294 (1), U01HL069301 (1), U10CA095861 (1), U24CA076518 (1), UG1CA189955 (1)